Risk Factors of Colectomy in Patients With  Refractory Ulcerative Colitis Under Calcineurin Inhibitors Combined With Vedolizumab

We have read with great interest the recently published article by Pellet et  al.1 The authors assessed the efficacy and safety of calcineurin inhibitors as an induction therapy combined with vedolizumab as a maintenance therapy in a cohort of patients with steroid and anti–tumor necrosis factor–refractory ulcerative colitis (UC), using colectomy-free survival as the pr imary end point. Interestingly, this retrospective study identified the female sex, the presence of hemoglobin (Hb) greater than 11.2 g/dL, age, and concomitant immunosuppressant as baseline factors associated with colectomy.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research